This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (228)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Nutritional and Metabolic Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Subgroup Analyses in the Scandinavian Simvastatin Survival Study

Steven M. Haffner, MD; Charles M. Alexander, MD; Thomas J. Cook, MS; Stephen J. Boccuzzi, PhD; Thomas A. Musliner, MD; Terje R. Pedersen, MD; John Kjekshus, MD; Kalevi Pyörälä, MD; for the Scandinavian Simvastatin Survival Study Group

Arch Intern Med. 1999;159:2661-2667.

Background  Patients with diabetes mellitus (DM) have a marked increase in coronary heart disease (CHD) events relative to those without DM. In a previous report from the Scandinavian Simvastatin Survival Study using a clinical case definition of DM (n = 202), simvastatin-treated patients had significantly fewer CHD events compared with placebo-treated control subjects.

Objective  To examine the effect of simvastatin therapy on CHD in patients with DM and impaired fasting glucose levels.

Methods  Using the 1997 American Diabetes Association diagnostic criteria, we assessed the effect of simvastatin therapy post hoc for an average of 5.4 years in Scandinavian Simvastatin Survival Study patients with normal fasting glucose (n = 3237), impaired fasting glucose (n = 678), and DM (n = 483).

Results  Simvastatin-treated patients with DM had significantly reduced numbers of major coronary events (relative risk [RR] = 0.58; P = .001) and revascularizations (RR = 0.52; P = .005). Total (RR = 0.79; P = .34) and coronary (RR = 0.72; P = .26) mortality were also reduced in DM, but not significantly, due to small sample size. In impaired fasting glucose (IFG) subjects, simvastatin use significantly reduced the number of major coronary events (RR = 0.62; P = .003), revascularizations (RR = 0.57; P = .009), and total (RR = 0.57; P = .02) and coronary (RR = 0.45; P = .007) mortality.

Conclusions  Our results extend previous findings in patients with DM to a larger cohort, confirming the benefit of cholesterol lowering with simvastatin treatment on CHD events. In addition, significant decreases in total mortality, major coronary events, and revascularizations were observed in simvastatin-treated patients with impaired fasting glucose levels. These results strongly support the concept that cholesterol lowering with simvastatin therapy improves the prognosis of patients with elevated fasting glucose levels ( 6.0 mmol/L [ 110 mg/dL]) or DM and known CHD.

From the Department of Medicine, University of Texas Health Science Center at San Antonio (Dr Haffner); US Medical & Scientific Affairs, Merck & Co Inc, West Point, Pa (Drs Alexander and Boccuzzi); Merck Research Laboratories, Rahway, NJ (Mr Cook and Dr Musliner); Cardiology Section, Medical Department, Aker Hospital (Dr Pedersen), and Section of Cardiology, Rikshospitalet (Dr Kjekshus), Oslo, Norway; and Department of Medicine, University of Kuopio, Kuopio, Finland (Dr Pyörälä). A list of members of the Scandinavian Simvastatin Survival Study Group appears in the Lancet, 1994;344:1388-1389.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

The Benefits of Lowering Cholesterol in Subjects With Mild Hyperglycemia
Ronald B. Goldberg
Arch Intern Med. 1999;159(22):2627-2628.
EXTRACT | FULL TEXT  

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(22):2751.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Should All Diabetic Patients Be Treated With a Statin?
Kamari et al.
Diabetes Care 2009;32:S378-S383.
FULL TEXT  

Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes
Hemmingsen et al.
Eur J Endocrinol 2009;161:1-9.
ABSTRACT | FULL TEXT  

CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Improved Survival of Diabetic Foot Ulcer Patients 1995-2008: Possible impact of aggressive cardiovascular risk management
Young et al.
Diabetes Care 2008;31:2143-2147.
ABSTRACT | FULL TEXT  

Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force
ANN INTERN MED 2008;148:846-854.
ABSTRACT | FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris et al.
ANN INTERN MED 2008;148:855-868.
ABSTRACT | FULL TEXT  

PROactive: time for a critical appraisal
Betteridge et al.
Eur Heart J 2008;29:969-983.
ABSTRACT | FULL TEXT  

Screening for Coronary Artery Disease in Patients With Diabetes
Bax et al.
Diabetes Care 2007;30:2729-2736.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Serum Lipids and Glucose Control: The SEARCH for Diabetes in Youth Study
Petitti et al.
Arch Pediatr Adolesc Med 2007;161:159-165.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed et al.
Eur Heart J 2006;27:2323-2329.
ABSTRACT | FULL TEXT  

Lipid-lowering therapy in type 2 diabetes: a review of the evidence
Steinmetz
Diabetes and Vascular Disease Research 2006;3:S10-S15.
ABSTRACT  

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Costa et al.
BMJ 2006;332:1115-1124.
ABSTRACT | FULL TEXT  

Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds
Grundy
J Am Coll Cardiol 2006;47:1093-1100.
ABSTRACT | FULL TEXT  

Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production
Erdos et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;290:H1264-H1270.
ABSTRACT | FULL TEXT  

Diabetes and Coronary Risk Equivalency: What does it mean?
Grundy
Diabetes Care 2006;29:457-460.
FULL TEXT  

REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT | FULL TEXT  

Evolving treatment paradigms for vascular risk reduction in type 2 diabetes: Report of an international symposium held in Barcelona, Spain, January 27-29, 2006
British Journal of Diabetes & Vascular Disease 2006;6:S1-S12.
 

Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial
Menard et al.
CMAJ 2005;173:1457-1466.
ABSTRACT | FULL TEXT  

Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
Van Gaal et al.
British Journal of Diabetes & Vascular Disease 2005;5:344-350.
ABSTRACT  

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT  

Management of patients with type 2 diabetes after acute coronary syndromes
Bartnik et al.
Diabetes and Vascular Disease Research 2005;2:144-154.
ABSTRACT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial
Geluk et al.
Eur Heart J 2005;26:1314-1320.
ABSTRACT | FULL TEXT  

Pathophysiology of dyslipidaemia in the metabolic syndrome
Kolovou et al.
Postgrad. Med. J. 2005;81:358-366.
ABSTRACT | FULL TEXT  

Barriers to Diabetes Education in Urban Patients: Perceptions, Patterns, and Associated Factors
Rhee et al.
The Diabetes Educator 2005;31:410-417.
ABSTRACT | FULL TEXT  

Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular Disease Risk Factors in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group
Diabetes Care 2005;28:888-894.
ABSTRACT | FULL TEXT  

Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia
Parris et al.
Diabetes Care 2005;28:595-599.
ABSTRACT | FULL TEXT  

Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Feig et al.
CMAJ 2005;172:177-180.
FULL TEXT  

Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease
Wannamethee et al.
Heart 2004;90:1398-1403.
ABSTRACT | FULL TEXT  

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
J Am Coll Cardiol 2004;44:720-732.
ABSTRACT | FULL TEXT  

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:e149-e161.
ABSTRACT | FULL TEXT  

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
Circulation 2004;110:227-239.
ABSTRACT | FULL TEXT  

Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
Pyorala et al.
Diabetes Care 2004;27:1735-1740.
ABSTRACT | FULL TEXT  

Treating dyslipidaemia in the patient with type 2 diabetes
Betteridge
Eur Heart J Suppl 2004;6:C28-C33.
ABSTRACT | FULL TEXT  

Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats
Miller et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004;287:R157-R160.
ABSTRACT | FULL TEXT  

Diabetes: preventing coronary heart disease in a high risk group
Feher
Heart 2004;90:iv18-iv21.
ABSTRACT | FULL TEXT  

The Burden of Diabetes-Associated Cardiovascular Hospitalizations in Veterans Administration (VA) and Non-VA Medical Facilities
Smith and Maynard
Diabetes Care 2004;27:B27-B32.
ABSTRACT | FULL TEXT  

Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT | FULL TEXT  

Multi-vessel coronary disease and percutaneous coronary intervention
Casey and Faxon
Heart 2004;90:341-346.
FULL TEXT  

Inpatient to Outpatient Transfer of Care in Urban Patients With Diabetes: Patterns and Determinants of Immediate Postdischarge Follow-up
Wheeler et al.
Arch Intern Med 2004;164:447-453.
ABSTRACT | FULL TEXT  

Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
Athyros et al.
ANGIOLOGY 2003;54:679-690.
ABSTRACT  

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose: Results from the LIPID trial
Keech et al.
Diabetes Care 2003;26:2713-2721.
ABSTRACT | FULL TEXT  

Epidemic Obesity and the Metabolic Syndrome
Haffner and Taegtmeyer
Circulation 2003;108:1541-1545.
FULL TEXT  

Associations of Diabetes Mellitus and Ethnicity with Mortality in a Multiethnic Asian Population: Data from the 1992 Singapore National Health Survey
Ma et al.
Am J Epidemiol 2003;158:543-552.
ABSTRACT | FULL TEXT  

Diabetes mellitus and cardiovascular risk: just another risk factor?
Torp-Pedersen et al.
Eur Heart J Suppl 2003;5:F26-F32.
ABSTRACT  

Sex Differences in Risk for Coronary Heart Disease Mortality Associated With Diabetes and Established Coronary Heart Disease
Natarajan et al.
Arch Intern Med 2003;163:1735-1740.
ABSTRACT | FULL TEXT  

Type 2 Diabetes and Coronary Heart Disease: We Keep Learning How Little We Know
Reaven
Arterioscler. Thromb. Vasc. Bio. 2003;23:917-918.
FULL TEXT  

Clinical trials of lipid-lowering medication in diabetes
Durrington
British Journal of Diabetes & Vascular Disease 2003;3:217-220.
ABSTRACT  

Prevention of Cardiovascular Ischemic Events: High-Risk and Secondary Prevention
Genest and Pedersen
Circulation 2003;107:2059-2065.
FULL TEXT  

Lipid Management in Patients With Diabetes: Translating guidelines into action
Inzucchi and Amatruda
Diabetes Care 2003;26:1309-1311.
FULL TEXT  

Dietary Fat Predicts Coronary Heart Disease Events in Subjects With Type 2 Diabetes
Soinio et al.
Diabetes Care 2003;26:619-624.
ABSTRACT | FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Harris et al.
ANN INTERN MED 2003;138:215-229.
ABSTRACT | FULL TEXT  

Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease
McFarlane and Sowers
J. Clin. Endocrinol. Metab. 2003;88:516-523.
FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Rubins et al.
Arch Intern Med 2002;162:2597-2604.
ABSTRACT | FULL TEXT  

Variation in Diabetes Care Among States: Do patient characteristics matter?
Arday et al.
Diabetes Care 2002;25:2230-2237.
ABSTRACT | FULL TEXT  

Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Sowers and Haffner
Hypertension 2002;40:781-788.
FULL TEXT  

Response to Lamotte et al.
Edelsberg et al.
Diabetes Care 2002;25:1899-1900.
FULL TEXT  

Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia
Athyros et al.
Diabetes Care 2002;25:1198-1202.
ABSTRACT | FULL TEXT  

New Strategies for the Treatment of Diabetic Dyslipidemia
Haffner and Goldberg
Diabetes Care 2002;25:1237-1239.
FULL TEXT  

A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors
Cheng et al.
Cardiovasc Res 2002;54:528-538.
ABSTRACT | FULL TEXT  

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: Lifestyle and Medical Management of Risk Factors
Grundy et al.
Circulation 2002;105 :e153-e158.
FULL TEXT  

Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers
McFarlane et al.
Diabetes Care 2002;25:718-723.
ABSTRACT | FULL TEXT  

Modifiable Cardiovascular Risk Factors in Adults With Diabetes: Prevalence and Missed Opportunities for Physician Counseling
Egede and Zheng
Arch Intern Med 2002;162:427-433.
ABSTRACT | FULL TEXT  

Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2002;87:423-437.
FULL TEXT  

The Impact of Outpatient Diabetes Management on Serum Lipids in Urban African-Americans With Type 2 Diabetes
Erdman et al.
Diabetes Care 2002;25:9-15.
ABSTRACT | FULL TEXT  

Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
Ballantyne et al.
Circulation 2001;104:3046-3051.
ABSTRACT | FULL TEXT  

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Rizos and Mikhailidis
Cardiovasc Res 2001;52:199-207.
ABSTRACT | FULL TEXT  

Prevention and Treatment of Coronary Heart Disease: Who Benefits?
LaRosa
Circulation 2001;104:1688-1692.
ABSTRACT | FULL TEXT  

Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
Sniderman et al.
ANN INTERN MED 2001;135:447-459.
ABSTRACT | FULL TEXT  

Lipid Disorders : Justification of Methods and Goals of Treatment
Braunstein et al.
Chest 2001;120:979-988.
ABSTRACT | FULL TEXT  

Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment
Wilhelmsen et al.
Eur Heart J 2001;22:1119-1127.
ABSTRACT  

Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management
Henry
Clin. Diabetes 2001;19:113-120.
ABSTRACT | FULL TEXT  

Response to Egede
Grover et al.
Diabetes Care 2001;24:1306-1307.
FULL TEXT  

Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease
Lefer et al.
Cardiovasc Res 2001;49:281-287.
FULL TEXT  

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?
Grover et al.
Diabetes Care 2001;24:45-50.
ABSTRACT | FULL TEXT  

Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy
Isles and Paterson
QJM 2000;93:567-574.
ABSTRACT | FULL TEXT  

Diabetes care needs evidence based interventions to reduce risk of vascular disease
Byrne and Wild
BMJ 2000;320:1554-1555.
FULL TEXT  

The Benefits of Lowering Cholesterol in Subjects With Mild Hyperglycemia
Goldberg
Arch Intern Med 1999;159:2627-2628.
FULL TEXT